BETHLEHEM, Pa., July 12, 2011 /PRNewswire/ — Particle
Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption
Systems, a leading provider of pre-clinical pharmacokinetic
services, announced today that the two companies are working
together to provide their clients with enhanced drug development
services by integrating pre-clinical pharmacokinetic data into the
dosage form development scheme.
According to Robert Lee, Ph.D., Particle Sciences’ Vice
President Pharmaceutical Development, “Particle Sciences has always
had a methodical approach to drug product development. Dosage
form design is best done when informed by the in vivo
solubility, permeability and metabolism of the drug. This is
true for oral drug products as well as other routes of
administration. Absorption Systems has put in place a scaled
in vitro / ex vivo / in vivo approach to
obtaining this data, which lends itself to our needs. For
those clients that desire it, Particle Sciences can integrate this
data stream into our drug product development plan.
Ultimately, this should prove to be a cost-effective way to
drive efficiency and minimize time to the clinic.”
Chris Bode, Ph.D., Vice President Scientific & Corporate
Communications at Absorption Systems, adds that “Our portfolio
includes a number of physicochemical and biological tests that can
make formulation development a more rational and efficient process.
Particle Sciences is a leader in drug formulation and
manufacturing, and we are very pleased that they are leveraging our
toolset in their efforts. I believe this is consistent with
their overall innovative and comprehensive approach to drug product
development”.
Absorption Systems, founded in 1996, assists
pharmaceutical and medical device companies in identifying and
overcoming ADMET (Absorption, Distribution, Metabolism, Excretion
and Toxicity) barriers in
‘/>”/>
